Sinai Hospital, who provided an overview of the known and potential AEs of GLP-1-based therapies
The REWIND cardiovascular outcome trial also revealed that dulaglutide administration resulted in inferior ocular outcomes, leading to an increased need for interventions such as photocoagulation, anti-vascular endothelial growth factor (VEGF) therapy, or vitrectomy compared to placebo recipients [38]
They are sold as supplements made with herbs, vitamins, or amino acids
10,17 GLP-1 receptor stimulation in the arcuate nucleus also improves glycemic control independent of feeding behavior
This is a transparency-and-interest analysis, not a clinical review
You know exactly what you will pay regardless of your dose, and that eliminates the unpleasant surprise of increasing costs as your treatment progresses